Interleukin-2 in metastatic melanoma: what is the current role?
Atkins, M.B.
Cancer Journal from Scientific American 6(Suppl 1): S8-10
2000
ISSN/ISBN: 1081-4442 PMID: 10685651 Document Number: 517790
Document emailed within 1 workday
Related Documents
Flaherty, D.C.; Deutsch, G.B.; Kirchoff, D.D.; Lee, J.; Huynh, K.T.; Lee, D.Y.; Foshag, L.J.; Bilchik, A.J.; Faries, M.B. 2015: Adrenalectomy for Metastatic Melanoma: Current Role in the Age of Nonsurgical Treatments American Surgeon 81(10): 1005-1009Dutcher, J.P. 2011: High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard Oncology 25(5): 427-428
García de Galdeano; Boyano, D.; Smith-Zubiaga, I.; Alvarez, A.; Cantón, I.; Cañavate, L. 1998: Involvement of interleukin-6 in the biology and metastatic activity of B16F10 melanoma cells European Cytokine Network 9(2): 187-192
Legha, S.S. 1997: Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy Seminars in Oncology 24(1 Suppl 4: S39-S43
Proebstle, T.M.; Scheibenbogen, C.; Sterry, W.; Keilholz, U. 1996: A phase II study of dacarbazine, cisplatin, interferon-alpha and high-dose interleukin-2 in 'poor-risk' metastatic melanoma European Journal of Cancer 32a(9): 1530-1533
Lee, D.S.; White, D.E.; Hurst, R.; Rosenberg, S.A.; Yang, J.C. 1998: Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy Cancer Journal From Scientific American 4(2): 86-93
Keilholz, U.; Scheibenbogen, C.; Stoelben, E.; Saeger, H.D.; Hunstein, W. 1994: Immunotherapy of metastatic melanoma with interferon-alpha and interleukin-2: pattern of progression in responders and patients with stable disease with or without resection of residual lesions European Journal of Cancer 30a(7): 955-958
Sznol, M.; Clark, J.W.; Smith, J.W.; Steis, R.G.; Urba, W.J.; Rubinstein, L.V.; VanderMolen, L.A.; Janik, J.; Sharfman, W.H.; Fenton, R.G. 1992: Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma Journal of the National Cancer Institute 84(12): 929-937
Patel, F.; Wilken, R.; Burrall, B.; Martinez, S.; Wells, V.; King, B.; Maverakis, E. 2014: Detailed protocol for administration of intralesional IL-2 for the treatment of Stage IIIc and IV M1a metastatic melanoma based on current NCCN guidelines Dermatology Online Journal 20(11)
Bailly, M.; Doré, J.F. 1992: Clonal drift and role of chromosome dosage in human melanoma metastatic cell lines: a statistical analysis Anticancer Research 12(4): 1163-1172
Lissoni, P.; Rovelli, F.; Baiocco, N.; Tangini, G.; Fumagalli, L. 2001: A phase Ii study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone Anticancer Research 21(1b): 777-779
Volkov, V.V.; Napol'skiĭ, V.P. 1986: The role of various current methods of treating patients with intraocular melanoma Oftalmologicheskii Zhurnal 7: 386-390
Barillé, S.; Bataille, R.; Amiot, M. 2000: The role of interleukin-6 and interleukin-6/interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma European Cytokine Network 11(4): 546-551
Saha, S.; Mohanty, K.C. 2003: Enhancement of metastatic potential of mouse B16-melanoma cells to lung after treatment with gangliosides of B-16-melanoma cells of higher metastatic potential to lung Indian Journal of Experimental Biology 41(11): 1253-1258
Itoh, K.; Tilden, A.B.; Balch, C.M. 1985: Role of interleukin 2 and a serum suppressive factor on the induction of activated killer cells cytotoxic for autologous human melanoma cells Cancer Research 45(7): 3173-3178
Frydland, M.; Elming, H.; Ahlehoff, O. 2014: Malignant melanoma with metastatic melanoma to the heart Ugeskrift for Laeger 176(25)
Castelli, C.; Sensi, M.; Lupetti, R.; Mortarini, R.; Panceri, P.; Anichini, A.; Parmiani, G. 1994: Expression of interleukin 1 alpha, interleukin 6, and tumor necrosis factor alpha genes in human melanoma clones is associated with that of mutated N-RAS oncogene Cancer Research 54(17): 4785-4790
Skowronek, J.; Roszak, A. 1997: A case of metastatic malignant melanoma of the vagina with a background of primary vaginal melanoma--clinical case Ginekologia Polska 68(8): 390-393
van Groningen, J.J.; Bloemers, H.P.; Swart, G.W. 1995: Identification of melanoma inhibitory activity and other differentially expressed messenger RNAs in human melanoma cell lines with different metastatic capacity by messenger RNA differential display Cancer Research 55(24): 6237-6243
Schilling, V.; Negri, B.; Bujía, J.; Schulz, P.; Kastenbauer, E. 1992: Possible role of interleukin 1 alpha and interleukin 1 beta in the pathogenesis of cholesteatoma of the middle ear American Journal of Otology 13(4): 350-355